Overview

Intratumoral Cisplatin for Resectable NSCLC

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

PRIMARY OBJECTIVE: To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol DESIGN: 3+3 dose escalation.

Phase:

Phase 1

Details

Lead Sponsor:

University of Vermont

Collaborator:

Johnson & Johnson

Treatments:

Cisplatin